New trends in the ovarian cancer treatment

Przeglad Menopauzalny

Volumn 17, Issue 6, 2013, Pages 489-492

  Marczak, Agnieszka ^a   Bukowska, Barbara ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Cancer stem cells; Multidrug resistance; Ovarian cancer

Indexed keywords

3',3' N XYLENYLBIS(DAUNORUBICIN); ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPOTHILONE DERIVATIVE; METFORMIN; MUELLERIAN INHIBITING FACTOR; MULTIDRUG RESISTANCE PROTEIN; SALINOMYCIN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE; CELL PROLIFERATION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER;

EID: 84892650074     PISSN: 16438876     EISSN: 22990038     Source Type: Journal    
DOI: 10.5114/pm.2013.39814     Document Type: Article

References (26)

1. Yang H, Chen B. CD147 in ovarian and other cancers, Int J Gynecol Cancer 2013; 23: 2-8.
2. Burgos-Ojeda D, Rueda BR, Buckanovich RJ. Ovarian cancer stem cell markers: Prognostic and therapeutic implications, Cancer Lett 2012; 322: 1-7.
3. Mutschler E., Antybiotyki działaja̧ce cytostatycznie. In: Farmakologia i toksykologia. Buczko W (eds.). Wydawnictwo MedPharm, Wrocław 2010; 971-3.
4. Dragojew S, Marczak A, Maszewski J, et al. The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts. Cell Mol Biol Lett 2008; 13: 182-94.
5. Brooks TA, O'Loughlin KL, Minderman H, et al. The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Invest New Drugs 2007; 25: 115-22.
6. Villamarín S, Ferrer-Miralles N, Mansilla S, et al. Induction of G(2)/M arrest and inhibition of c-myc and p53 transcription by WP631 in Jurkat T lymphocytes. Biochem Pharmacol 2002; 63: 1251-8.
7. Rogalska A, Gajek A, Szwed M, et al. The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: A comparison with the effect of doxorubicin. Toxicol In Vitro 2011; 25: 1712-20.
8. Lee JJ, Swain SM. The epothilones - translating from the laboratory to the clinic. Clin Cancer Res 2008; 14: 1618-24.
9. Cheng KL, Bradley T, Budman DR. Novel microtubule-targeting agents - the epothilones. Biologics 2008; 2: 789-811.
10. Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009; 63: 201-12.
11. Kumar A, Heise H, Blommers MJ, et al. Interaction of epothilone B (patupilone) with microtubules as detected by two-dimensional solid-state NMR spectroscopy. Angew Chem Int Ed Engl 2010; 49: 7504-7.
12. Rogalska A, Marczak A, Gajek A, et al. Induction of apoptosis in human ovarian cancer cells by new anticancer compounds, epothilone A and B. Toxicol In Vitro 2013; 27: 239-49.
13. Ferrandina G, Martinelli E, Petrillo M, et al. CD133 antigen expression in ovarian cancer. BMC Cancer 2009; 9: 221.
14. Baba T, Convery PA, Matsumura N, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009; 28: 209-18.
15. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005; 65: 3025-9.
16. Lee TK, Castilho A, Cheung VC, et al. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011; 9: 50-63.
17. Silva IA, Bai S, McLean K, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011; 71: 3991-4001.
18. Statkiewicz M, Małecki M. Macierzyste komórki nowotworowe a oporność nowotworów na terapiȩ. Nowotwory 2009; 59: 456-63.
19. Metformax, Charakterystyka Produktu Leczniczego (Centrum Informacji o Leku, available at: leki-informacje.pl).
20. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69: 7507-11.
21. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab- resistant tumor-initiating breast cancer stem cells. Breast Cancer Res Treat 2011; 126: 355-64.
22. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008; 110: 246-50.
23. Yasmeen A, Beauchamp MC, Piura E, et al. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol 2011; 121: 492-8.
24. Shank JJ, Yang K, Ghannam J, et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol 2012; 127: 390-7.
25. Meirelles K, Benedict LA, Dombkowski D, et al. Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance, Proc Natl Acad Sci U S A 2012; 109: 2358-63.
26. Zhang B, Wang X, Cai F, et al. Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK. Tumour Biol 2012; 33: 1855-62.